Original Articles

CIC-rearranged Sarcomas

A Study of 20 Cases and Comparisons With Ewing Sarcomas

Yoshida, Akihiko MD, PhD; Goto, Keisuke MD; Kodaira, Makoto MD, MBA; Kobayashi, Eisuke MD, PhD; Kawamoto, Hiroshi MD; Mori, Taisuke DMD, PhD; Yoshimoto, Seiichi MD; Endo, Otone MD; Kodama, Narihito MD, PhD; Kushima, Ryoji MD, PhD; Hiraoka, Nobuyoshi MD, PhD; Motoi, Toru MD, PhD; Kawai, Akira MD, PhD

Author Information
The American Journal of Surgical Pathology 40(3):p 313-323, March 2016. | DOI: 10.1097/PAS.0000000000000570

Abstract

The CIC gene rearrangement exists in a subset of small round cell sarcomas. As the nosologic relationship of these sarcomas to Ewing sarcomas remains undetermined, we examined 20 CIC-rearranged sarcomas to compare their clinicopathologic features with those of Ewing sarcomas. The CIC-rearranged sarcomas were from a group of 14 men and 6 women with a median age of 24.5 years. The primary tumor sites included the limbs, trunk wall, internal trunk, lung, cerebrum, and pharynx. A comparison of the demographic and clinical characteristics of the 20 patients with CIC-rearranged sarcomas with those of the 53 near-consecutive patients with EWSR1-rarranged Ewing sarcomas showed that there were no differences with respect to their ages and sexes. Although none of the CIC-rearranged sarcomas arose in the bone, 40% of the Ewing sarcomas primarily affected the skeleton. The overall survival of patients with Ewing sarcomas was significantly better than that for patients with CIC-rearranged sarcomas. A histologic comparison of the CIC-rearranged sarcomas with 20 EWSR1-rearranged Ewing sarcomas showed significantly higher degrees of lobulation, nuclear pleomorphism, the prominence of the nucleoli, spindle cell elements, and myxoid changes in the CIC-rearranged sarcomas. Distinguishing immunohistochemical features included heterogenous CD99 reactivity, nuclear WT1 expression, and calretinin expression in the CIC-rearranged sarcomas and NKX2.2 expression in the Ewing sarcomas. CIC-rearranged sarcomas are distinct from Ewing sarcomas clinically, morphologically, and immunohistochemically, and they should be considered a separate entity rather than being grouped within the same family of tumors.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid